Introduction: More than half of the patients with inflammatory bowel disease (IBD) experience at least one extra-intestinal manifestation (EIM). The most common EIM in patients with IBD is spondyloarthritis (SpA). Microscopic intestinal inflammation is documented in almost 50% of the patients with SpA.
Introduction
Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling conditions 1, 2 . More than half of the patients with IBD experience at least one extra-intestinal manifestation (EIM) 3 . The most common EIM in patients with IBD is spondyloarthritis (SpA) 4 . SpA is a group of diseases with similar clinical, radiological and serological features. It includes ankylosing spondylitis (AS), also defined as radiographic axial SpA (r-axSpA), nonradiographic axial SpA (nr-axSpA), psoriatic arthritis, reactive arthritis, IBD-associated SpA and undifferentiated SpA (uSpA) 5 . SpA causes a significant burden to the patient and to the society [6] [7] [8] [9] . Microscopic intestinal inflammation is documented in approximately 50% of patients with SpA 10 , and 7% of these patients develop IBD 11 . An integrated management of A c c e p t e d M a n u s c r i p t patients with coexisting IBD and SpA, with cooperation between the gastroenterologist and the rheumatologist, is necessary to provide the best possible care. Most anti-tumor necrosis factor (anti-TNF) agents work for both diseases 12, 13 . Only etanercept, an anti-TNF agent licensed for the use in patients with AS, is not a treatment option in patients with IBD.
Ustekinumab, a monoclonal antibody that binds to the p40 subunit of interleukin-12 and interleukin-23, proved efficacy in patients with CD 14 and in patients with psoriatic arthritis 15 , but its value in patients with (non-)radiographic axial SpA remains unclear. Whether drugs with a gut-specific mode of action, such as vedolizumab, work for IBD-related arthritis is debated.
Herein, we give an overview of the classification, the epidemiology and the diagnosis of IBD and SpA. The treatment goals, the pharmacologic management options and the available treatment guidelines in IBD patients with SpA are discussed. Finally, an expert opinion about the treatment of patients with coexisting IBD and SpA is provided.
Methodology
We searched for relevant manuscripts in PubMed/MEDLINE, EMBASE (Excerpta Medica A c c e p t e d M a n u s c r i p t controlled trials and meta-analyses published in the last 5 years. Relevant abstracts presented at major meetings were also considered.
Epidemiology
A recent meta-analysis assessed the prevalence and incidence of peripheral and axial SpA in IBD patients 16 . The authors included 71 studies reporting on the prevalence of sacroiliitis, AS, arthritis, enthesitis and dactylitis in 27524 patients. SpA occurred in up to 13% of patients with IBD. A detailed description about the criteria used for diagnosing SpA is lacking, but the authors state that in 56.3% of the studies 'objective standard criteria for the measurement of SpA' were used and that 'SpA was measured reliable' in 46.5% of patients. The pooled prevalence of sacroiliitis was 10% (95% confidence interval (CI) 8-12%), the pooled prevalence of AS was 3% (95% CI 2-4%) and the pooled prevalence of peripheral arthritis was 13% (95% CI 12-15%). The prevalence of sacroiliitis, AS and peripheral arthritis was higher in CD patients compared to UC patients 16 . Earlier data report evidence of radiologic sacroiliitis in 20% to 50% of IBD patients [17] [18] [19] . In a cohort study with a duration of almost 2 years in a combined gastroenterology-rheumatology clinic, 269/1495 (18%) IBD patients reported musculoskeletal pain. Enteropathic SpA was diagnosed in 136/269 (50.5%) of these patients 20 . To establish the diagnosis of enteropathic SpA, clinical and biochemical data were collected and joint imaging, including ultrasound (US) and traditional radiography for the assessment of peripheral involvement (arthritis, enthesitis, dactylitis) and traditional radiography and magnetic resonance imaging (MRI) for the assessment of axial involvement, was requested when appropriate 20 . In a multicenter study evaluating the subclinical affected A c c e p t e d M a n u s c r i p t prevalence was higher in the IBD patients than in the healthy controls, but there was no difference between the IBD and the SpA patients 21 .
Diagnosis

Diagnosing SpA in IBD patients
SpA is classified according to the Assessment in SpondyloArthritis international Society criteria, distinguishing peripheral from axial SpA (table 1) 22, 23 . The positive predictive value of these sets of criteria is 89.5% for peripheral SpA and 93.3% for axial SpA 24 . European
Crohn's and Colitis Organisation (ECCO) consensus describes a diagnostic approach for arthritis in IBD patients (table 2) 3 . Given the non-erosive character of peripheral arthritis, especially oligoarthritis, conventional radiography is usually normal and the recognition of IBD-related peripheral SpA remains mainly clinical (eg. joint swelling and tenderness) 25 .
When clinical exam alone is doubtful, US examination or MRI may be used to confirm peripheral enthesitis or to detect peripheral arthritis, tenosynovitis and bursitis 26 . The diagnosis of axial SpA in IBD patients is based on the combination of inflammatory low back pain associated with conventional radiographic or MRI features of sacroiliitis 3 . Inflammatory back pain must be suspected in the presence of 2 or more of the following features, and the presence of 4 or more of these features are considered diagnostic: onset before 45 years, insidious onset, duration of more than 3 months, morning stiffness more than 30 minutes, improvement with exercise, no improvement with rest, awaking from pain and alternating buttock pain 27 . Added to clinical and biological data, MRI analysis contributes to an earlier diagnosis of axial SpA in patients with IBD Nevertheless, only 51% of those patients was seen by a rheumatologist. In that group of patients, SpA was diagnosed in 58% of the cases, while another rheumatic disorder was found in 21% 33 . Subsequently, patients with symptoms of SpA may be underdiagnosed and effective treatment may be delayed, which can lead to a chronic debilitating disease course and a decreased quality of life 34 . The use of a SpA self-reported questionnaire in IBD patients led to an increased recognition of SpA 35 . Diagnostic clues that should trigger the gastroenterologist to refer the patient for further rheumatologic evaluation are summarized in 
Diagnosing IBD in SpA patients
The diagnosis of IBD is made by clinical evaluation and a combination of biochemical, endoscopic, histological and/or radiological data 36, 37 . Importantly, IBD can still be asymptomatic at the time that patients present with musculoskeletal symptoms 38 . 
Treatment goals
Treatment goals in IBD
The STRIDE (Selecting Therapeutic Targets in Inflammatory Bowel Disease) consensus defined mucosal healing in combination with resolution of symptoms as one of the major treatment goals for patients with IBD 41 . Mucosal healing is associated with sustained clinical remission, steroid-free remission, and reduced rates of hospitalization and surgery in CD 42, 43 .
In UC, studies demonstrated the association of mucosal healing with improved long-term clinical outcomes and a reduced risk of colectomy [44] [45] [46] [47] . However, all data available on the value of mucosal healing as a target in IBD are mainly retrospective or circumstantial, and disease-modifying studies in IBD are scarce 48 . Also, the definition of mucosal healing is debated in both CD and UC, and the current definitions, based on cut-offs of endoscopic activity indices, are less favorable to be used as an instrument for disease remission 49, 50 . The STRIDE consensus did not retain biomarkers as a treatment target 41 . In the recent CALM study, a treat-to-target strategy based on a composite target of tight control of biomarkers (fecal calprotectin and CRP) and clinical symptoms (Crohn's disease activity index or CDAI) was superior to standard care based on symptom control alone. Significantly more patients A c c e p t e d M a n u s c r i p t achieved mucosal healing with absence of deep ulcers after 1 year 51 . In UC, Osterman et al.
showed that a calprotectin-guided approach in aminosalicylates treated patients reduced relapse rates 52 . In 52 patients with UC in remission but with fecal calprotectin >50 μg/g taking multimatrix mesalamine 2.4g/day, mesalamine was either continued at the same dose or increased by 2.4 g/day for 6 weeks. The primary outcome of continued remission with fecal calprotectin <50 μg/g was achieved by 3.8% of controls and 26.9% of the dose escalation group (p=0.05). More patients in the dose escalation group reduced fecal calprotectin to below 100 μg/g (p=0.04) and 200 μg/g (p=0.005). Clinical relapse occurred sooner in patients with fecal calprotectin >200 μg/g compared to those with fecal caprotectin <200 μg/g (p=0.01) 52 . Nevertheless, whether treat-to-target strategies in IBD patients will prevent negative long-term outcomes, such as disability and bowel damage in CD, is yet to be established, whereas in another inflammatory disease such as rheumatoid arthritis (RA), evidence has accumulated over the last decade 48, 53, 54 .
Treatment goals in SpA
Similar to RA and CD, the treatment goals in SpA are maintenance of physical function, control of disease activity and prevention of organ damage 55 . The primary treatment goal of axial SpA is, according to the updated ASAS-EULAR management recommendations, to maximise long-term health-related quality of life trough control of symptoms and inflammation, prevention of progressive structural damage, preservation or normalisation of function and social participation 56 . A predefined target when initiating therapy is recommended to achieve this goal 56 . Recently, the association between disease activity and progression of tissue damage was established in patients with early axial SpA and secukinumab, an anti-interleukin-17A monoclonal antibody, is a well-established treatment option for AS 60 . Nevertheless, both have no place in the specific treatment of IBD and will therefore not be discussed separately in this section.
Aminosalicylates
There is a lack of evidence for the use of 5-aminosalicylates (olsalazine and mesalamine) in CD 61, 62 . Sulfasalazine shows low efficacy for the treatment of active CD 62 , but its incidental side effects should be taken into account when initiated 36 . Oral 5-aminosalicylates are highly effective for inducing and maintaining remission in mild to moderate UC [63] [64] [65] . Also sulfasalazine is effective in the treatment of UC 66 .
Sulfasalazine treatment was not more effective than placebo in a 24-week trial in patients with A c c e p t e d M a n u s c r i p t
Corticosteroids
Two historical trials established corticosteroids as an effective therapy in inducing remission in CD 71, 72 . Both topically (oral budesonide) and systemically acting corticosteroids can be used, depending on the disease distribution and severity. Although good at inducing remission, steroids are ineffective for maintaining remission in CD 36 . In UC, systemic corticosteroids are appropriate in patients with moderate to severe activity and in those with mild activity who do not respond to mesalamine. Topical acting oral steroids (beclomethasone dipropionate) can also be used in patients with mild to moderately active disease 66 .
Furthermore, budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and proctosigmoiditis 73 . In acute severe UC, intravenously administration of methylprednisolone 60 mg each 24 hours or hydrocortisone 100 mg four times daily is promptly warranted 66, 74 .
Systemic corticosteroid therapy is not recommended in the current treatment guidelines for axial SpA 56, 69 . Only high dose (50 mg daily) of oral prednisone was effective in patients with . Systemic corticosteroids can also be given in case of peripheral flare, but rapid tapering is required 69 .
Immunomodulators
Thiopurine therapy (azathioprine and 6-mercaptopurine) offers no advantage over placebo for induction of remission or clinical improvement in active CD, although it allows patient to reduce steroid consumption 77 . In UC, thiopurines are efficacious in patients who flare when steroids are withdrawn 78, 79 . Furthermore, thiopurine therapy appears to be more effective than .
Anti-TNF therapy
Numerous randomized controlled trials support the use of anti-TNF therapy in the treatment of CD and UC [92] [93] [94] [95] . Anti-TNF therapy remains the cornerstone in the treatment of IBD A c c e p t e d M a n u s c r i p t CD, and golimumab is only labelled for the use in UC 36, 66 . Both infliximab and adalimumab can be used in the case of complex fistulising perianal disease, in conjunction with surgical drainage, but the level of evidence is lower for adalimumab compared to infliximab [96] [97] [98] [99] .
Infliximab, adalimulab, golimumab and certolizumab pegol have approval, both in the EU and in the USA, for the use in patients with AS (r-axSpA), as multiple treatment trials showed improvement in clinical symptoms, CRP levels and MRI-detectable inflammation in the sacroiliac joints and spine in these patients 27, 76 . Adalimumab, golimumab and certolizumab pegol, but not infliximab, seem to be equally effective in patients with nr-axSpA as in patients with r-axSpA 100 . . Altogether, there is a need for large cohort studies exploring the potential benefit of vedolizumab on IBDassociated SpA.
Ustekinumab
Ustekinumab is a monoclonal antibody that binds to the p40 subunit common to interleukin- . There are no data available on the use of selective JAK1 inhibitors in SpA.
Treatment guidelines in patients with IBD and SpA
An Italian expert panel developed therapeutic algorithms in patients with IBD and SpA depending on the disease activity of both entities 5 . Based on these principles, also a very patients without active IBD and should be limited to short periods in time.
Summary
SpA is the most common EIM in IBD and occurs in up to 13% of patients. On the other hand, A c c e p t e d M a n u s c r i p t mode of action, such as vedolizumab, work for IBD-related arthritis is still debated. NSAIDs use for SpA can only be considered in patients without active IBD and should be limited to short periods in time.
Expert commentary
The coexistence of IBD and SpA generates challenges as well as opportunities for both the gastroenterologist and the rheumatologist.
Although concomitant IBD and SpA is frequent, awareness in health care practitioners remains low and too often a well-structured multidisciplinary management is not offered to the patient. Therefore, regular deliberation between the gastroenterologist and the rheumatologist, for example in a monthly multidisciplinary team meeting, can optimise care
by giving the opportunity to discuss complex cases and make jointly treatment decisions.
Joint complaints in IBD patients are often difficult to deal with and a broad differential diagnosis exists. Mainly arthralgia (joint pain without inflammation) and arthritis (joint pain with objective signs of inflammation) need to be distinguished. Arthralgia in IBD patients can be caused by the introduction of thiopurines 128, 129 or by the withdrawal of corticosteroids 130 .
It is also a common side effect in patients treated with anti-TNF therapy 131, 132 . Furthermore, corticosteroid-related osteonecrosis and infliximab-related lupus-like syndrome can mimic SpA in IBD patients 133, 134 . A c c e p t e d M a n u s c r i p t vasculitis are part of the differential diagnosis. An expert advice by a gastroenterologist to choose the most appropriate diagnostic strategy is warranted.
Practitioners need to be aware that management options for SpA can influence the IBD disease course in a negative way. NSAIDs are a first-line treatment option for SpA but increase the risk of IBD relapse 135, 136 . Some data suggest that the use of COX-2 inhibitors may be safer than conventional NSAIDs 137, 138 , but this needs to be confirmed. We support the general idea that the use of NSAIDs in IBD patients should be avoided when possible, although short-term use is acceptable when necessary A c c e p t e d M a n u s c r i p t
Five-year view
To develop better treatment strategies for patients with concomitant IBD and SpA, we need a more profound understanding of the underlying disease mechanisms that play in these patients. Research will focus around two major topics in the upcoming years: the role of drugs with a gut-specific mode of action in the treatment of concomitant rheumatic disease and the role of gut microbiota in the pathogenesis of IBD and SpA.
Real-life experience of the use of vedolizumab and more prospectively collected data in large cohort studies will clarify the effect of the drug in the treatment of IBD-related arthritis. We belief that vedolizumab will more likely have a beneficial, rather than a paradoxical, effect in patients with concomitant IBD and SpA. Several recent clinical data support this expectation [111] [112] [113] . 
4.
NSAIDs for SpA can only be considered in patients without active IBD and should be limited to short periods in time.
5. The potential of drugs with a gut-specific mode of action in the treatment of IBDrelated arthritis warrants further exploration. M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 
